(COG ANBL0032) Phase III Randomized Study of Chimeric Antibody 14.18 (Ch14.18) in High Risk Neuroblastoma Following Myeloablative Therapy and Autologous Stem Cell Rescue
Description: 

The primary objective of this study is to determine if monoclonal antibody CH14.18 +cytokinews+isotretinoin improves event free survival after myeloablative therapy and stem cell rescue as compared to RA alone, in high risk neuroblastoma pts who have achieved a pre-ASCT response of CR, VGPR, or PR.

Study Number: 

NCG 63405

Phase: 
III
Principal Investigator: 
ClinicalTrials.Gov ID: 
NCT00026312

To inquire about participating in these studies, call 1-877-ASK-RPCI (1-877-275-7724) or e-mail askrpci@roswellpark.org.